Related Experiment Video
Updated: Jun 27, 2026
13:38
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Aspirin resistance: focus on clinical endpoints
Gabriella Pusch1, Gergely Feher, Katalin Kotai
1Department of Neurology, University of Pecs, School of Medicine, Pecs, Hungary.
Journal of Cardiovascular Pharmacology
|November 27, 2008
Summary
Aspirin resistance, where platelets function normally despite treatment, is linked to worse outcomes in high-risk patients. Standardized definitions and treatments for aspirin resistance are currently lacking.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Research
Background:
- Aspirin effectively reduces arterial thrombotic events by ~25% in high-risk individuals.
- A significant percentage of patients on aspirin experience recurrent events, prompting investigation into aspirin resistance.
- Aspirin resistance is defined as normal platelet function in patients undergoing aspirin therapy.
Purpose of the Study:
- To systematically review evidence on aspirin resistance prevalence and its clinical outcome association.
- To identify potential treatment strategies for aspirin resistance.
Main Methods:
- Systematic literature review of studies published up to March 2008.
- Analysis of data from various laboratory methods assessing aspirin resistance.
- Collection of articles detailing treatment approaches.
Main Results:
- Aspirin resistance appears to correlate with adverse clinical outcomes.
- No universally accepted definition or standardized laboratory methods for aspirin resistance currently exist.
- Laboratory methods for assessing aspirin resistance may not be comparable.
Conclusions:
- Aspirin resistance is associated with poor clinical outcomes, but definitions are not standardized.
- Lack of comparable laboratory methods hinders definitive treatment recommendations.
- Further research is needed to establish clear guidelines for managing aspirin resistance.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:25Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...